Skip to main content
LAB logo

LAB · Standard Biotools Inc.

Track LAB — free
$0.63 +0.02 (+2.82%) At close · Nov 20
Market Cap
$249.11M
Shares
394.79M
Volume · Nov 20 2.81M Avg daily vol (3M) 1.2M

Price & Indicators

 

Key stats

Close
$0.63
Fri 20 Nov
Open
$0.63
Fri 20 Nov
Average volume, 30 days
973K
shares a session
Short interest
2.2M
0.5% of shares · 3.1 days to cover
Day range
$0.57$0.65
Open $0.63 Close $0.63
52-week closing range
$0.54$1.68
Close $0.63 62.4% under the high
Short volume, last session
75%
Last earnings
Aug 11, 2025
Latest filing
10-Q · Nov 3
Price history
Jan 2020 to Nov 2026

Up next

call held May 6, 2025

Latest documents

2026
Nov 19
Current report 8-K
Stockholders approve Treeline merger, reverse split and name change

Standard BioTools stockholders approved all seven proposals at a November 19, 2026 special meeting, including share issuance tied to the Merger with Treeline Biosciences. The approved charter amendment covers a reverse stock split at a ratio in the range from 1-for-20 to 1-for-40 and a name change to Treeline Biosciences, Inc. The Element Mass Cytometry divestiture was also approved, with 276,299,544 votes for.

Director or officer change, or executive pay, Shareholder vote results, Regulation FD disclosure Read from the first part of this long document
4 source passages
On November 19, 2026, the Company held a virtual special meeting of stockholders effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio in the range from 1-for-20 to 1-for-40, inclusive, with the final ratio to be mutually agreed to by the Company and Treeline Biosciences, Inc., and (ii) change the name of the Company to “Treeline Biosciences, Inc.” The proposal to approve the Element Mass Cytometry Divestiture (as defined in the Proxy Statement/Prospectus), which may be considered a sale of substantially all of the assets of the Company under Section 271 of the Delaware General Corporation Law, was approved by the following votes: 276,299,544 Open the document at this passage
Nov 16
Current report 8-K
Supplemental merger disclosures follow litigation challenges

Standard BioTools Inc. voluntarily supplemented merger disclosures after 15 demand letters and two stockholder complaints alleged omissions in materials for its Treeline merger, ahead of the November 19, 2026 stockholder meeting.

Other events
5 source passages
As previously disclosed, on June 6, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools” or the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among the Company, Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”). In connection with the Merger, between July 27, 2026 and November 9, 2026, the Company received 15 demand letters, including one demand made pursuant to Section 220 of the Delaware General Corporation Law seeking certain books and records of the Company, from purported stockholders of the Company (the “Demand Letters”). In addition, on October 29, 2026 and October 30, 2026, purported stockholders of the Company filed two complaints in the Supreme Court of the State of New York, County of New York, captioned Carroll v. Standard BioTools Inc., et al., Index No. 656182/2026, and Miller v. Standard BioTools Inc., et al., Index No. 656185/2026, respectively (together, the “Complaints”). the Company has determined voluntarily to supplement certain disclosures in the Definitive Proxy Statement/Prospectus related to the claims with the supplemental disclosures set forth below (the “Supplemental Disclosures”). The Registration Statement includes a proxy statement/prospectus with respect to the special meeting of the Company’s stockholders scheduled to be held on November 19, 2026 (the “Special Meeting”) in connection with the Merger. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Treeline merger expected to close in fourth quarter 2026

Standard BioTools expects its merger with Treeline Biosciences to close in the fourth quarter of 2026, with existing shareholders holding approximately 16% of the combined company. Stockholders are scheduled to vote on November 19, 2026.

Revenue $19.39M ▼ 0.9% Net income $13.48M Diluted EPS $0.03
Read from the MD&A section
3 source passages
The Merger is expected to close in the fourth quarter of 2026. Following the closing (the “Closing”), our existing stockholders are expected to hold approximately 16% of the combined company on a fully diluted basis, and former Treeline stockholders are expected to hold approximately 84%, subject to adjustment in accordance with the Merger Agreement. The special meeting of our stockholders to vote on the proposals related to the Merger and the sale of the Mass Cytometry Business is scheduled for November 19, 2026. Open the document at this passage
Nov 3
Current report 8-K
Microfluidics business sale completed and renamed Biomark Scientific

Standard BioTools completed the sale of its Microfluidics business to ARCHIMED on November 3, 2026; the standalone business will operate as Biomark Scientific.

Regulation FD disclosure
2 source passages
November 3, 2026 –Global private equity healthcare specialist ARCHIMED, and Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools”), today announced the completion of ARCHIMED’s previously announced acquisition of Standard BioTools’ Microfluidics Business. As part of ARCHIMED, the business enters its next chapter as a standalone business under the name Biomark Scientific. Open the document at this passage
Oct 21
Registration statement S-4/A
Treeline merger and Element divestiture need stockholder votes

Standard BioTools agreed on June 6, 2026 to combine with Treeline Biosciences in an all-stock merger, with former Treeline stockholders expected to hold approximately 84% of the combined company. Stockholders will vote on the share issuance, a reverse stock split at a ratio in the range of 1-for-20 to 1-for-40, and the Element Mass Cytometry Divestiture. Element's purchase agreement was signed on September 30, 2026.

Read from the first part of this long document
5 source passages
As previously announced, on June 6, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), entered into an Agreement and Plan of Merger and Reorganization former Treeline stockholders are expected to hold approximately 84% of the combined company on a fully diluted basis at a ratio in the range from 1-for-20 to 1-for-40, inclusive To approve the Element Mass Cytometry Divestiture, which may be considered a sale of substantially all of the assets of Standard BioTools under Section 271 of the Delaware General Corporation Law On September 30, 2026, Standard BioTools entered into a Share and Asset Purchase Agreement Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$84.43M
Trailing 12 months
Net income (TTM)
$133.08M
Trailing 12 months
Revenue growth YoY
-0.9%
Year over year
Operating margin
-97.5%
Trailing 12 months
P / E (TTM)
1.9
Trailing earnings · reciprocal yield 53.9%
FCF yield
-26.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.9%
Year over year · more shares
Price change (1Y)
-50.7%
Trailing year
Short interest
0.5%
Latest settlement · 3.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −26%
below
Price vs 50-day avg −6%
below
RSI (14) 49
neutral
MACD trend Negative
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +4%
trailing
6-month return −46%
trailing
YTD return −51%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-27% holders QoQ · +8 funds added
Insider flow Accumulating
Net +$46.9K over 90 days · 0% sells
Short interest Falling
0.55% of shares out · ▼ -11.3% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
104 holders — mid 3-yr range
Squeeze score 40
elevated · 0–100
Fundamentals
Strong
Revenue growth −2%
Y/Y
Gross margin 42%
contracting
EPS growth +62%
Y/Y
Free cash flow $-82.6M
Valuation P/E 1.9
below peers
Buyback $9.5M
remaining
Balance sheet $166.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −68%
past year
ATR 10.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the 8-K filed May 5, 2026
Revenue · fiscal year 2026 Maintained $80M – $85M
Feb 24, 2026 $80M – $85M changed to May 5, 2026 $80M – $85M
prior FY $85.33M midpoint −3.3% Y/Y
Guided vs delivered · last 4 settled
FY 2024 Revenue full year 2024
guided $170M – $175M
$91.01M Miss −47.2%
Total revenue full year 2023
guided $100M – $105M
$106.34M Beat +3.7%
Total Revenue 2021
guided $123M – $127M
$130.58M Beat +4.5%
Total revenue Q4 2021
guided $31M – $34M
$38.27M Beat +17.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
−6% Bearish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-27% holders QoQ · +8 funds added
Insider flow Accumulating
Net +$46.9K over 90 days · 0% sells
Short interest Falling
0.55% of shares out · ▼ -11.3% MoM · 3.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
104 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 8% Range high $2
vs 200-day avg -26% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP -$5.6M Six Months Ended June 30, 2026 —
Non-GAAP gross margin percentage non-GAAP 57% Six Months Ended June 30, 2026 —
Non-GAAP gross profit non-GAAP $23.52M Six Months Ended June 30, 2026 —
Non-GAAP operating expenses non-GAAP $29.11M Six Months Ended June 30, 2026 —
Non-GAAP R&D operating expenses non-GAAP $3.42M Six Months Ended June 30, 2026 —
Non-GAAP SG&A operating expenses non-GAAP $25.7M Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LAB
Standard Biotools Inc.
this stock
$249.11M -50.7% -2.4% 1.9 0.5%
ABT
Abbott Laboratories
$178.39B -17.8% +5.7% 38.4 1.1%
MDT
Medtronic plc
$127.84B +4.0% +8.4% 24.6 1.8%
SYK
Stryker Corp
$118.01B -11.8% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$60.85B -56.0% +12.5% 17.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
104
% held
73.3%
Net QoQ
-6.7M sh
Top holder
Casdin Capital, LLC
Held Float
View
Held by Funds
Fund positions
47
View
Short & Settlement
Short Interest Falling
Shares short
2.2M
Days to cover
3.1d
Change
-275.9K sh
View
Short Volume
Short vol %
75%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
50.4K
Value
$31.3K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
45.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$46.9K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$85.3M
Net income (FY)
$-74.9M
EPS diluted
$-0.20
View
Buybacks
Authorized
$50.0M
Remaining
$9.5M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 19, 2026
This year
31

Standard BioTools stockholders approved all seven proposals at a November 19, 2026 special meeting, including share issuance tied to the Merger with Treeline Biosciences. The approved charter amendment covers a reverse stock split at a ratio in the range from 1-for-20 to 1-for-40 and a name change to Treeline Biosciences, Inc. The Element Mass Cytometry divestiture was also approved, with 276,299,544 votes for.

View
Proposed Sales
Value
$12.4K
Shares
13.2K
Filed
May 23, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Standard BioTools Stockholders Ap…
Published
Nov 19, 2026
View

Performance

5D 20D 120D MTD YTD
LAB -10.8% +4.2% -45.6% +3.4% -50.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -2.2% +13.4% -36.4% +12.2% -51.9%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$50.00M
Spent (derived)
$40.50M
Remaining
$9.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1162194 CUSIP 34385P108 13F (30d) 121 filings 100 filers Visit website Investor relations